News & events Upcoming events Apr 15, 2023 - Apr 18, 2023 33rd ECCMID Copenhagen, Denmark More info and meet us there Apr 17, 2023 - Apr 17, 2023 Le nuove raccomandazioni del consiglio europeo sugli screening oncologici Rome, Italy More info and meet us there Apr 22, 2023 - Apr 27, 2023 AAN 2023 - American Academy of Neurology Boston (MA), United States of America More info and meet us there See all upcoming events Latest news Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Mar 8, 2023 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics... Read more Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more Load More
Apr 17, 2023 - Apr 17, 2023 Le nuove raccomandazioni del consiglio europeo sugli screening oncologici Rome, Italy More info and meet us there
Apr 22, 2023 - Apr 27, 2023 AAN 2023 - American Academy of Neurology Boston (MA), United States of America More info and meet us there
Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more
Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
Mar 8, 2023 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics... Read more
Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more
Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more
May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more
